Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Dabrafenib + Trametinib & Biliary tract cancer / Cholangiocarcinoma (BRAF m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Approval status

The FDA has approved a treatment for unresectable or metastatic solid tumors with the BRAF V600E mutation, applicable after prior therapy when no satisfactory alternatives exist. This approval includes eligible cases of biliary tract cancer, also known as cholangiocarcinoma. However, it is important to note that no EMA approval has been verified for biliary tract cancer or cholangiocarcinoma (1)

References

(1) FLASCO / FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation

see al…

References (Sources)

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Subbiah et al. 2020 The Lancet Oncology 21: 1234-1243

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!